- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV1 vector system (AAV1 expression system, AAV1 packaging plasmid system ) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi (GM) AAV1 Vector system is including: 1) AAV1 Rep-Cap plasmid (AAV1-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).
You can produce AAV1 particle in 293T cell line in high titer using GeneMedi's AAV1 Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV1 vector has been validated in neuron(CNS), heart, muscle, retina and Pancreas, with potential applications in tissue-specific gene therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.
Go to AAV
vector system
>>Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-PK01 | AAV1 Vector System (Amp resistance) 1. AAV1 Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Academic | 2028 | ||
| P-PK01 | AAV1 Vector System (Amp resistance) 1. AAV1 Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-PK01 | AAV1 Vector System (Amp resistance) 1. AAV1 Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK01 | AAV1 Vector System (Amp resistance) 1. AAV1 Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK01-Kan | AAV1 Vector System (Kan resistance) 1. AAV1 Rep-Cap Plasmid (Kan resistance) , ≥10mg 2. AAV Helper Plasmid (Kan resistance) , ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-RC01 | AAV1 Rep-Cap
Plasmid (Amp resistance)
Size：5ug |
Academic | 935 | ||
| P-RC01 | AAV1 Rep-Cap
Plasmid (Amp resistance)
Size：5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-RC01 | AAV1 Rep-Cap
Plasmid (Amp resistance)
Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC01 | AAV1 Rep-Cap
Plasmid (Amp resistance)
Size：≥10mg |
All | |||
| P-RC01-Kan | AAV1 Rep-Cap
Plasmid(Kan resistance)
Size：≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides | Nature | 2023/12/13 |
| Discovery of a potent allosteric activator of DGKQ that ameliorates obesity-induced insulin resistance via the sn-1, 2-DAG-PKCε signaling axis | Cell Metabolism | 2022/12/15 |
| Histone demethylase JMJD3 downregulation protects against aberrant force-induced osteoarthritis through epigenetic control of NR4A1 | International Journal of Oral Science | 2022/7/14 |
| Observing Extracellular Vesicles Originating from Endothelial Cells in Vivo Demonstrates Improved Astrocyte Function Following Ischemic Stroke via Aggregation-Induced Emission Luminogens | ACS nano | 2023/8/3 |
| Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy | Advanced Science | 2022/8/10 |
| ATF3 -activated accelerating effect of LINC00941/lncIAPF on fibroblast-to-myofibroblast differentiation by blocking autophagy depending on ELAVL1/HuR in pulmonary fibrosis | Autophagy | 2022/4/15 |
| Epigenetic controls of Sonic hedgehog guarantee fidelity of epithelial adult stem cells trajectory in regeneration | Science Advances | 2022/7/22 |
| ETS-1 facilitates Th1 cell-mediated mucosal inflammation in inflammatory bowel diseases through upregulating CIRBP | Journal of Autoimmunity | 2022/8/1 |
| Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer | Autophagy | 2023/9/29 |
| Circular RNA FEACR inhibits ferroptosis and alleviates myocardial ischemia/reperfusion injury by interacting with NAMPT | Journal of Biomedical Science | 2023/6/27 |
Validation data
Figure. Selected transduction results of AAV in vitro (in 293T cell line)
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
